Accuray (ARAY) Competitors

$0.31 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.33 +0.02 (+7.20%)

As of 05/22/2026 07:49 PM Eastern

ARAY vs. RMTI, ISRG, ABT, SYK, and MDT

Should you buy Accuray stock or one of its competitors? MarketBeat compares Accuray with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Accuray include Rockwell Medical (RMTI), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Stryker (SYK), and Medtronic (MDT). These companies are all part of the "health care equipment" industry.

How does Accuray compare to Rockwell Medical?

Rockwell Medical (NASDAQ:RMTI) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Rockwell Medical has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Accuray has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

23.3% of Rockwell Medical shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 3.6% of Rockwell Medical shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rockwell Medical currently has a consensus target price of $2.00, suggesting a potential upside of 152.18%. Accuray has a consensus target price of $2.00, suggesting a potential upside of 551.68%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Rockwell Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Rockwell Medical had 1 more articles in the media than Accuray. MarketBeat recorded 2 mentions for Rockwell Medical and 1 mentions for Accuray. Rockwell Medical's average media sentiment score of 0.52 beat Accuray's score of 0.30 indicating that Rockwell Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rockwell Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rockwell Medical has a net margin of -7.98% compared to Accuray's net margin of -10.76%. Rockwell Medical's return on equity of -15.41% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.98%	-15.41%	-9.62%
Accuray	-10.76%	-79.43%	-10.38%

Accuray has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26M	0.45	-$5.31M	-$0.15	N/A
Accuray	$458.51M	0.08	-$1.59M	-$0.37	N/A

Summary

Rockwell Medical beats Accuray on 10 of the 16 factors compared between the two stocks.

How does Accuray compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Accuray (NASDAQ:ARAY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	15.42	$2.86B	$8.25	53.10
Accuray	$458.51M	0.08	-$1.59M	-$0.37	N/A

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Intuitive Surgical presently has a consensus price target of $579.33, suggesting a potential upside of 32.24%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 551.68%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than Intuitive Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Intuitive Surgical has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Accuray has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

In the previous week, Intuitive Surgical had 45 more articles in the media than Accuray. MarketBeat recorded 46 mentions for Intuitive Surgical and 1 mentions for Accuray. Intuitive Surgical's average media sentiment score of 1.03 beat Accuray's score of 0.30 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	32 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intuitive Surgical has a net margin of 28.15% compared to Accuray's net margin of -10.76%. Intuitive Surgical's return on equity of 15.98% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Accuray	-10.76%	-79.43%	-10.38%

Summary

Intuitive Surgical beats Accuray on 14 of the 16 factors compared between the two stocks.

How does Accuray compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and Accuray (NASDAQ:ARAY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Abbott Laboratories has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Accuray has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Abbott Laboratories presently has a consensus price target of $119.43, indicating a potential upside of 36.62%. Accuray has a consensus price target of $2.00, indicating a potential upside of 551.68%. Given Accuray's higher probable upside, analysts plainly believe Accuray is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Abbott Laboratories had 32 more articles in the media than Accuray. MarketBeat recorded 33 mentions for Abbott Laboratories and 1 mentions for Accuray. Abbott Laboratories' average media sentiment score of 1.35 beat Accuray's score of 0.30 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	28 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.44	$6.52B	$3.57	24.49
Accuray	$458.51M	0.08	-$1.59M	-$0.37	N/A

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 4.4% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abbott Laboratories has a net margin of 13.90% compared to Accuray's net margin of -10.76%. Abbott Laboratories' return on equity of 17.62% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Accuray	-10.76%	-79.43%	-10.38%

Summary

Abbott Laboratories beats Accuray on 14 of the 17 factors compared between the two stocks.

How does Accuray compare to Stryker?

Accuray (NASDAQ:ARAY) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Accuray has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Stryker has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

64.1% of Accuray shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 4.4% of Accuray shares are held by company insiders. Comparatively, 4.6% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$458.51M	0.08	-$1.59M	-$0.37	N/A
Stryker	$25.12B	4.83	$3.25B	$8.64	36.62

In the previous week, Stryker had 17 more articles in the media than Accuray. MarketBeat recorded 18 mentions for Stryker and 1 mentions for Accuray. Stryker's average media sentiment score of 1.12 beat Accuray's score of 0.30 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stryker	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Accuray presently has a consensus target price of $2.00, suggesting a potential upside of 551.68%. Stryker has a consensus target price of $395.48, suggesting a potential upside of 25.00%. Given Accuray's higher probable upside, research analysts plainly believe Accuray is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stryker has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Stryker's return on equity of 23.42% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Stryker	13.20%	23.42%	11.04%

Summary

Stryker beats Accuray on 14 of the 16 factors compared between the two stocks.

How does Accuray compare to Medtronic?

Accuray (NASDAQ:ARAY) and Medtronic (NYSE:MDT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Accuray currently has a consensus price target of $2.00, indicating a potential upside of 551.68%. Medtronic has a consensus price target of $106.45, indicating a potential upside of 35.33%. Given Accuray's higher possible upside, equities analysts clearly believe Accuray is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

Accuray has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$458.51M	0.08	-$1.59M	-$0.37	N/A
Medtronic	$33.54B	3.01	$4.66B	$3.59	21.91

In the previous week, Medtronic had 24 more articles in the media than Accuray. MarketBeat recorded 25 mentions for Medtronic and 1 mentions for Accuray. Medtronic's average media sentiment score of 0.88 beat Accuray's score of 0.30 indicating that Medtronic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medtronic	16 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Medtronic has a net margin of 13.00% compared to Accuray's net margin of -10.76%. Medtronic's return on equity of 14.82% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Medtronic	13.00%	14.82%	7.88%

64.1% of Accuray shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 4.4% of Accuray shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Medtronic beats Accuray on 13 of the 16 factors compared between the two stocks.

Get Accuray News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAY vs. The Competition

Export

Metric	Accuray	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.51M	$7.10B	$6.46B	$12.34B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-0.83	47.45	20.99	25.66
Price / Sales	0.08	73.72	559.58	86.31
Price / Cash	6.88	24.91	43.49	56.67
Price / Book	0.88	6.53	10.44	7.14
Net Income	-$1.59M	$158.81M	$3.57B	$335.98M
7 Day Performance	7.38%	3.61%	6.37%	4.11%
1 Month Performance	-33.99%	0.74%	3.51%	2.52%
1 Year Performance	-80.45%	3.17%	34.10%	35.04%

Accuray Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAY Accuray	2.6975 of 5 stars	$0.31 flat	$2.00 +551.7%	-80.5%	$36.51M	$458.51M	N/A	1,040
RMTI Rockwell Medical	3.3329 of 5 stars	$0.78 -1.4%	$2.00 +156.0%	-19.0%	$30.84M	$67.68M	N/A	300
ISRG Intuitive Surgical	4.1807 of 5 stars	$439.92 +4.5%	$579.33 +31.7%	-18.8%	$149.15B	$10.06B	53.32	17,021	Positive News Analyst Downgrade
ABT Abbott Laboratories	4.9551 of 5 stars	$87.82 +4.0%	$119.43 +36.0%	-33.4%	$147.13B	$45.13B	24.60	115,000	Positive News
SYK Stryker	4.973 of 5 stars	$312.99 +2.0%	$395.48 +26.4%	-16.1%	$117.60B	$25.12B	36.23	56,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAY) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accuray (ARAY) Competitors

ARAY vs. RMTI, ISRG, ABT, SYK, and MDT

How does Accuray compare to Rockwell Medical?

Summary

How does Accuray compare to Intuitive Surgical?

Summary

How does Accuray compare to Abbott Laboratories?

Summary

How does Accuray compare to Stryker?

Summary

How does Accuray compare to Medtronic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accuray (ARAY) Competitors

ARAY vs. RMTI, ISRG, ABT, SYK, and MDT

How does Accuray compare to Rockwell Medical?

Which has more volatility and risk, RMTI or ARAY?

Do insiders & institutionals hold more shares of RMTI or ARAY?

Do analysts recommend RMTI or ARAY?

Does the media prefer RMTI or ARAY?

Is RMTI or ARAY more profitable?

Which has better earnings and valuation, RMTI or ARAY?

Summary

How does Accuray compare to Intuitive Surgical?

Which has preferable earnings and valuation, ISRG or ARAY?

Do insiders & institutionals hold more shares of ISRG or ARAY?

Do analysts rate ISRG or ARAY?

Which has more risk & volatility, ISRG or ARAY?

Does the media refer more to ISRG or ARAY?

Is ISRG or ARAY more profitable?

Summary

How does Accuray compare to Abbott Laboratories?

Which has more risk and volatility, ABT or ARAY?

Do analysts rate ABT or ARAY?

Does the media favor ABT or ARAY?

Which has preferable valuation & earnings, ABT or ARAY?

Do insiders and institutionals believe in ABT or ARAY?

Is ABT or ARAY more profitable?

Summary

How does Accuray compare to Stryker?

Which has more risk & volatility, ARAY or SYK?

Do insiders & institutionals hold more shares of ARAY or SYK?

Which has higher earnings and valuation, ARAY or SYK?

Does the media prefer ARAY or SYK?

Do analysts rate ARAY or SYK?

Is ARAY or SYK more profitable?

Summary

How does Accuray compare to Medtronic?

Do analysts prefer ARAY or MDT?

Which has more volatility and risk, ARAY or MDT?

Which has stronger valuation & earnings, ARAY or MDT?

Does the media favor ARAY or MDT?

Is ARAY or MDT more profitable?

Do insiders and institutionals believe in ARAY or MDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools